• 제목/요약/키워드: Microvessel

검색결과 91건 처리시간 0.019초

Human Lung Cancer에서 면역세포화학적 방법을 이용한 Tumor Angiogenesis에 관한 연구 (A study of Tumor Angiogenesis in Human Lung Cancer by Immunohistochemical Stain)

  • 천선희;김성숙;라선영;정현철
    • Tuberculosis and Respiratory Diseases
    • /
    • 제43권6호
    • /
    • pp.894-902
    • /
    • 1996
  • 연구배경: Tumor angiogenesis란 종양 내에서 및 종양을 향한 새로운 혈관 증식을 말하는 것으로 암의 중식과 전이의 원인이 되며, 주로 유방암과 전립선암에서 암세포 조직 내에서의 angiogenesls와 전이의 상관관계가 보고되었으며, angiogenesls의 정도가 암의 독립적인 중요한 예후인자로 보고되었다. 본 연구는 폐암 조직에서 anglogenesls의 정도를 측정하여 예후인자로서의 가치를 평가하고자하였다. 방법: 1990년 1월 부터 1994년 12월 까지 이화여대 부속 동대문병원에서 원발성 폐암으로 진단받고 치료성적 및 생존여부를 알고 있는 비소세포폐암(non-small cell lung cancer) 환자의 기관지내시경 조직의 paraffin embedded block을 이용하여 CD31에 대한 antibody인 JC70을 사용하여 면역세포화학적 방법으로 endothelial cell을 염색하였다. 결과: 1) 전체 29예에서 microvessel의 수는 $32.7{\pm}20.8$(9-96)개 였다. 2) Microvessel의 수와 폐암의 조직학적 유형, T staging 간에는 유의한 상관관계가 없었으며, 임파선 전이 (N staging) 및 혈성 전이 (M staging) 와도 관계가 없었다(p>0.05). 3) 대상환자의 평균 추적기간은 15개월(2-46)로 microvessel의 수가 20개 이상인 군(20예)과 이하인(9예) 군으로 나누어 보았을때 1년 생존률 각각 50%, 46%, 2년 생존율 각각 30%, 0%로 유의한 차이가 없었다(p>0.05). 결론: Tumor angiogenesis는 임파선 및 원발 전이의 가능성을 시사하는 중요한 예후 예측인자일 것으로 생각되나 폐암의 기관지내시경 조직검사 조직을 이용하여서 angiogenesis의 정도를 측정하는 것은 조직이 적절하지 못하고 측정이 제한적이었으며, 아직까지는 우리나라에서 폐암에서의 angtogenesls에 관한 연구가 없는 상태로 수술조직을 이용한 더 많은 연구가 필요할 것으로 생각된다.

  • PDF

설암에서 신부가화학요법후 미세혈관밀도에 대한 종양관련 대식세포의 역할 (THE ROLE OF TUMOR-ASSOCIATED MACROPHAGES ON MICROVESSEL DENSITY AFTER NEOADJUVANT CHEMOTHERAPY IN TONGUE CANCER)

  • 박봉욱;정인교;김종렬;김욱규;박봉수;김규천;변준호
    • Journal of the Korean Association of Oral and Maxillofacial Surgeons
    • /
    • 제32권3호
    • /
    • pp.209-215
    • /
    • 2006
  • Preoperative neoadjuvant chemotherapy using cisplatin and 5-FU is generally given in oral and maxillofacial cancer. At tissue level both inflammation and fibrosis occur after chemotherapy. The cellular changes mimic those of a granulating wound, with activated macrophages and fibroblasts replacing the malignant cells as they are erradicated. Stromal cells, together with extracellular matrix components, provide the microenvironment that is pivotal for tumor cell growth, invasion, and metastatic progression. Vascular endothelial growth factor(VEGF), an important regulator of angiogenesis in cancer, induces mitogenesis of vascular endothelial cells, and vascular permeabilization and microvessel formation in a tumor are associated with tumor nutrition and oxygenation. Also, they are associated with chemotherapeutic drug delivery. Oxygen delivery to tumor appears to rely on a network of microvessels, On the other hand, the tumor microvessel is clearly an important factor in chemotherapeutic drug delivery to cancer cells, and the efficacy of drug delivery can be high in richly vascularized tumors. So, this study was conducted to evaluate the effect of neoadjuvant chemotherapy on microvessel density from 11 patients with tongue cancers. Our results showed that neoadjuvant chemotherapy was seemed to decrease VEGF expression in tumor cells, however, it did not significantly alter VEGF expression in tumor-associated macrophages. Also, Neoadjuvant chemotherapy had little effect on the microvessel density using CD34, and tumor-associated macrophage level using CD68. Thus, tumorassociated macrophages seem to be the key factor associated with the maintenance of microvessel density after neoadjuvant chemotherapy in tongue cancer.

Characteristics of Invasive Breast Ductal Carcinoma, NOS, Diagnosed in a Tertiary Institution in the East Coast of Malaysia with a Focus on Tumor Angiogenesis

  • Ch'ng, Ewe Seng;Sharif, Sharifah Emilia Tuan;Jaafar, Hasnan
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제13권9호
    • /
    • pp.4445-4452
    • /
    • 2012
  • Background: Prognosis of breast cancer depends on classic pathological factors and also tumor angiogenesis. This study aimed to evaluate the clinicopathological factors of breast cancer in a tertiary centre with a focus on the relationship between tumor angiogenesis and clinicopathological factors. Methods: Clinicopathological data were retrieved from the archived formal pathology reports for surgical specimens diagnosed as invasive ductal carcinoma, NOS. Microvessels were immunohistochemically stained with anti-CD34 antibody and quantified as microvessel density. Results: At least 50% of 94 cases of invasive breast ductal carcinoma in the study were advanced stage. The majority had poor prognosis factors such as tumor size larger than 50mm (48.9%), positive lymph node metastasis (60.6%), and tumor grade III (52.1%). Higher percentages of estrogen and progesterone receptor negative cases were recorded (46.8% and 46.8% respectively). Her-2 overexpression cases and triple negative breast cancers constituted 24.5% and 22.3% respectively. Significantly higher microvessel density was observed in the younger patient age group (p=0.012). There were no significant associations between microvessel density and other clinicopathological factors (p>0.05). Conclusions: Majority of the breast cancer patients of this institution had advanced stage disease with poorer prognostic factors as compared to other local and western studies. Breast cancer in younger patients might be more proangiogenic.

Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma

  • Woo, Jong-Yun;Yang, Seung Ho;Lee, Youn Soo;Lee, Su Youn;Kim, Jeana;Hong, Yong Kil
    • Journal of Korean Neurosurgical Society
    • /
    • 제58권5호
    • /
    • pp.426-431
    • /
    • 2015
  • Objective : The purpose of this study was to evaluate the clinical efficacy of continuous low-dose temozolomide (TMZ) chemotherapy for recurrent and TMZ-refractory glioblastoma multiforme (GBM) and to study the relationship between its efficacy and microvessel density within the tumor. Methods : Thirty patients who had recurrent GBM following Stupp's regimen received TMZ daily at $50mg/m^2/day$ until tumor progression between 2007 and 2013. The median duration of continuous low-dose TMZ administration was 8 weeks (range, 2-64). Results : The median progression-free survival (PFS) of continuous low-dose TMZ therapy was 2 months (range, 0.5-16). At 6 months, PFS was 20%. The median overall survival (OS) from the start of this therapy to death was 6 months (95% CI : 5.1-6.9). Microvessel density of recurrent tumor tissues obtained by reoperation of 17 patients was $22.7{\pm}24.1/mm^2$ (mean${\pm}$standard deviation), and this was lower than that of the initial tumor ($61.4{\pm}32.7/mm^2$) (p-value=0.001). It suggests that standard TMZ-chemoradiotherapy reduces the microvessel density within GBM and that recurrences develop in tumor cells with low metabolic burden. The efficacy of continuous low-dose TMZ could not be expected in recurrent GBM cells in poor angiogenic environments. Conclusion : The efficacy of continuous low-dose TMZ chemotherapy is marginal. This study suggests the need to develop further treatment strategies for recurrent and TMZ-refractory GBM.

Microvessel Density as a Prognostic Factor in Ovarian Cancer: a Systematic Review and Meta-analysis

  • He, Lei;Wang, Qiao;Zhao, Xia
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권3호
    • /
    • pp.869-874
    • /
    • 2015
  • Background: The prognostic value of microvessel density (MVD), reflecting angiogenesis, detected in ovarian cancer is currently controversial. Here we performed a meta-analysis of all relevant eligible studies. Materials and Methods: A comprehensive search of online PubMed, Medline, EMBASE and Sciencedirect was performed to identify all related articles. The search strategy was designed as 'microvessel density', 'ovarian cancer', 'ovarian neoplasm', 'CD34' and 'angiogenesis'. Results: The studies were categorized by author/year, number of patients, FIGO stage, histology, cutoff value for microvessel density, types of survival analysis, methods of hazard rations (HR) estimation, HR and its 95% confidence interval (CI). Combined hazard ratios suggested that high MVD was associated with poor overall survival (OS) and progression-free survival (PFS), with HR and 95% CIs of 1.84 (1.33-2.35) and 1.36 (1.06-1.66), respectively. Subgroup analysis showed that high MVD detected by CD34 was relevant for OS [HR=1.67 (1.36-2.35)], but not MVD detected with other antibodies [HR=2.11 (0.90-3.31)]. Another subgroup analysis indicated that high MVD in patients without pre-chemotherapy, but not with pre-chemotherapy, was associated with OS [HR=1.88(1.59-2.18 and HR=1.70 (-0.18-3.59)]. Conclusions: The OS and PFS with high MVD were significant poorer than with low MVD in ovarian cancer patients. However, high MVD detected by CD34 seems to be more associated with survival for patients without pre-chemotherapy.

Measurement of Leukocyte Motions in a Microvessel Using Spatiotemporal Image Analysis

  • Kim, Jin-Woo
    • Journal of information and communication convergence engineering
    • /
    • 제6권3호
    • /
    • pp.315-319
    • /
    • 2008
  • This paper describes a method for recognizing and measuring the motion of each individual leukocyte in microvessel from a sequence of images. A spatiotemporal image is generated whose spatial axes are parallel and vertical to vessel region contours. In order to enhance and extract only leukocyte traces with a turned velocity range even under noisy background, we use a combination of a filtering process using Gabor filters with sharp orientation selectivity and a subsequent 3D spatiotemporal grouping process. The proposed method is shown to be effective by experiments using image sequences of two kinds of microcirculation, rat mesentery microvessels and human retinal capillaries.

Ki-67 Immunostaining and its Correlation with Microvessel Density in Patients with Mutiple Myeloma

  • Himani, Bhankar;Meera, Sikka;Abhimanyu, Sharma;Usha, Rusia
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제17권5호
    • /
    • pp.2559-2564
    • /
    • 2016
  • Purpose: To compare Ki-67 index and microvessel density MVD) in multiple myeloma and non-myeloma patients and their correlation with each other and other prognostic markers. Materials and Methods: Forty patients were enrolled in this study between 2011-2013, 30 with multiple myelomas and 10 with non-malignant disease as controls. Proliferative activity was analyzed by Ki-67 and microvessel density (MVC) was assessed by CD34 and compared between two groups. In myeloma patients, correlation between Ki-67, MVD and other prognostic factors was assessed by Pearson correlation coefficient. Results: According to Durie Salmon staging criteria, 13 patients were of stage 1, 5 of stage II and 12 of stage III. Ki-67 expression showed a positive correlation with MVD (r=0.729, p<0.001) and was significantly higher (p<0.0001) in myeloma patients (range 35-80%, mean 60.1 %) as compared to controls (range 8-25%, mean 18.1%). $MVD/mm^2$ was also significantly (p<0.0001) higher in myeloma patients (range $62-237/mm^2$, mean $178.0/mm^2$) than controls (range $5.2-50/mm^2$, mean $18.3/mm^2$). Ki-67 and MVD, both increased progressively with increasing stage of myeloma. Ki-67 showed significant positive correlation with blood urea and lactate dehydrogenase and a significant negative correlation with serum albumin. MVD showed a significant positive correlation with blood urea, lactate dehydrogenase, serum creatinine, ${\beta}2$ microglobulin and skeletal lesions. Conclusions: Ki-67 and MVD are indicators of aggressiveness and poor prognosis having significant correlation with each other and other prognostic markers of multiple myeloma. Routine assessment of these markers may help to identify high risk patients, who may benefit from with more aggressive therapy.

LCN2 Promoter Methylation Status as Novel Predictive Marker for Microvessel Density and Aggressive Tumor Phenotype in Breast Cancer Patients

  • Meka, Phanni bhushann;Jarjapu, Sarika;Nanchari, Santhoshi Rani;Vishwakarma, Sandeep Kumar;Edathara, Prajitha Mohandas;Gorre, Manjula;Cingeetham, Anuradha;Vuree, Sugunakar;Annamaneni, Sandhya;Dunna, Nageswara Rao;Mukta, Srinivasulu;Triveni, B;Satti, Vishnupriya
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권12호
    • /
    • pp.4965-4969
    • /
    • 2015
  • LCN2 (Lipocalin 2) is a 25 KD secreted acute phase protein, reported to be a novel regulator of angiogenesis in breast cancer. Up regulation of LCN2 had been observed in multiple cancers including breast cancer, pancreatic cancer and ovarian cancer. However, the role of LCN2 promoter methylation in the formation of microvessels is poorly understood. The aim of this study was to analyze the association of LCN 2 promoter methylation with microvessel formation and tumor cell proliferation in breast cancer patients. The LCN2 promoter methylation status was studied in 64 breast cancer tumors by methylation specific PCR (MSP). Evaluation of microvessel density (MVD) and Ki67 cell proliferation index was achieved by immunohistochemical staining using CD34 and MIB-1 antibodies, respectively. LCN2 promoter unmethylation status was observed in 43 (67.2%) of breast cancer patients whereas LCN2 methylation status was seen in 21 (32.8%). Further, LCN2 promoter unmethylation status was associated with aggressive tumor phenotype and elevated mean MVD in breast cancer patients.

타액선 선양낭성암종에서 혈관형성 신호전달 물질의 발현과 미세혈관농도에 관한 면역조직화학적 연구 (IMMUNOHISTOCHEMICAL ASSAYS FOR THE EXPRESSION OF ANGIOGENIC SIGNALING MOLECULES AND MICROVESSEL DENSITY IN ADENOID CYSTIC CARCINOMAS OF HUMAN SALIVARY GLANDS)

  • 박영욱;인연수
    • Journal of the Korean Association of Oral and Maxillofacial Surgeons
    • /
    • 제32권6호
    • /
    • pp.530-543
    • /
    • 2006
  • Adeonoid cystic carcinoma (ACC) is one of the most common malignant tumors of salivary glands. It is characterized by a relentless regrowth especially around nerve tissues and a high rate of hematogenous distant metastasis. Clinically most deaths from salivary ACC are caused by delayed lung metastases that are resistant to conventional chemotherapy. So, knowledge of cellular and molecular properties that influence the dissemination of metastatic tumor cells, is important for new treatment strategies of metastatic lesions. We determined expressions of angiogenic signaling molecules microvessel density (MVD) using surgical specimens of human salivary ACC. Protein expressions of vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR)-2, activated VEGFR-2, and human CD31 were assessed in 20 cases of salivary ACC by immunohistochemical staining. Most of the tumors, especially ACC with a tubulocribriform pattern, were positive for antibodies of VEGF, VEGFR-2, and activated VEGFR-2. The overall percentages of the 20 specimens expressing VEGF, VEGFR-2, activated VEGFR-2 were 90, 95, and 95%, respectively. Immunoreactivities of the biomarkers in salivary ACC were higher than those in normal salivary gland. Furthermore, immune-related cells as well as tumor cells expressed VEGF/VEGFR-2. Microvessel density of salivary ACC was higher than that of normal salivary gland (P<0.05). Taken together, angiogenic signaling molecules are actively expressed in salivary ACC. And we suggest that these molecules may have critical role in the hematogenous spread of salivay ACC, which has a propensity for delayed lung metastasis. Therefore, these biomarkers can be molecular targets for therapy of metastasis of salivary ACC.

원발성 비소세포 폐암에 있어서 미세혈판 신생의 임상적 예후인자로서의 의의 (Prognostic Significance of Angiogenesis in Non-Small Cell Lung Cancer)

  • 고혁재;박정현;국향;양세훈;정은택
    • Tuberculosis and Respiratory Diseases
    • /
    • 제48권5호
    • /
    • pp.757-765
    • /
    • 2000
  • 연구배경 : 혈관신생은 종양의 성장과 전이의 과정에 중요한 역할을 하며, 환자의 생존율과 예후에 영향을 미칠 것으로 생각된다. 혈관신생의 형성 정도를 반영하는 종양내 미세혈관 밀도가 비소세포 폐암에서 예후인자로서 유용하리라 생각되어, 미세혈관 밀도의 정도에 따른 생존 기간의 차이를 확인하여 미세혈관 밀도의 예후인자로서의 의의를 검색하고자 하였다. 대상 및 방법 : 1991년 1월부터 1997년 6월까지 원광대학병원에서 근치적 절제술을 시행받은 비소세포 폐암 50례(편평상피암 35례, 선암 12례, 대세포암 3례)를 대상으로 하여, 수술에 의해 채취된 paraffin 보관 조직의 절편을 이용하였다. 혈관신생의 정도로서 미세혈관 밀도를 혈관내피세포에 대한 표지자인 anti CD 31(PECAM, platelet endothelial cellular adhesion molecule)을 연역조직화학적 염색법으로 광학 현미경 200배 시야에서 계측하였다. 결과 : 전 대상군에서의 미세혈관 밀도는 47.1$\pm$17.7이었고 편평상피암 군은 43.9$\pm$16.2로서 선암군의 54.4$\pm$19.9 보다 유의하게 낮았으며(p<0.05), TNM 병기별 I 병기 50.6$\pm$16.2, II 병기 43.6$\pm$20.4, III 병기 43.8$\pm$17.9로서 TNM 병기별로 미세혈관 밀도의 차이는 없었다. 미세혈관 밀도가 45미만인 저밀도군(22례)과 45이상인 고밀도군(28례)의 중앙 생존기간은 61개월, 46개월이고 2년 생존율은 80%, 75%이고 5년 생존율은 40%, 12%로서, 미세혈관 저밀도군이 고밀도군보다 통계적으로 유의하게 생존율이 양호하였다 (p=0.0162, Kaplan-Meier, log-rank). 전 군을 병리조직학별로, TNM 병기별로 구분하여 미세혈관 저밀도군과 고밀도군으로 중앙생존기간을 비교한 결과 각각에 있어서 저밀도군의 중앙 생존기간이 양호하였으나, 각 군의 대상 례가 적용 탓으로 통계적 유의성에 이르지는 못하였다. 결론 : 혈관신생을 반영하는 미세혈관 밀도가 낮을수록 예후 및 생존율은 유의하게 양호하였으며, 미세혈관 밀도는 비소세포 폐암 환자에 있어서 예후추정인자로서 유용 하리라 생각된다.

  • PDF